MBX Biosciences, Inc. Common Stock

Stock Chart, Company Information, and Scan Results

$37.25(as of Jun 11, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

MBX Biosciences, Inc. Common Stock Company Information, Fundamentals, and Technical Indicators

Stock Price$37.25
Ticker SymbolMBX
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees63
CountyUSA
Market Cap$1,475.0M

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

MBX Biosciences, Inc. Common Stock In Our Stock Scanner

As of Jun 12, 2026
As of ---
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
As of ---
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.